NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announces the signing of a definitive agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity Inc. (“Celularity”) (NASDAQ: CELU), a regenerative and cellular medicine company. An accomplished commercial and scientific team is expected to join NEXGEL as part of the transaction, significantly expanding the Company’s sales organization and bringing deep domain expertise in regenerative biomaterials.
Read the full article: NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products //
Source: https://www.globenewswire.com/news-release/2026/03/10/3252840/0/en/NEXGEL-Signs-Definitive-Agreement-to-License-and-Acquire-Transformative-Portfolio-of-Commercial-Stage-Regenerative-Biomaterial-Products.html